A Phase 2, Open-Label, Multiple-Dose Study Investigating the Efficacy and Safety of Panhematin in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.
Phase of Trial: Phase II
Latest Information Update: 28 Oct 2014
At a glance
- Drugs Hemin (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- 23 Oct 2014 Status changed from completed to discontinued as reported by ClinicalTrials.gov record.
- 20 May 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 08 May 2007 New trial record.